Fear of pregnancy loss and fetal karyotyping: A place for third-trimester amniocentesis?

Fetal Diagnosis and Therapy

Volumn 23, Issue 1, 2008, Pages 30-35

  Picone, Olivier ^a,b   Senat, Marie Victoire ^a,b   Rosenblatt, Jonathan ^a,b   Audibert, François ^c   Tachdjian, Gerard ^a,b   Frydman, Rene ^a,b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b INSERM   (France)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Amniocentesis; Chorioamnionitis; Fetal loss; Fluorescence in situ hybridization; Karyotyping; Preterm birth; Preterm premature rupture of membranes; Third trimester

Indexed keywords

ADULT; AMNIOCENTESIS; ARTICLE; CHROMOSOME ABERRATION; FEMALE; FETUS; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; KARYOTYPE; LABOR; MAJOR CLINICAL STUDY; MATERNAL AGE; MEDICAL RECORD REVIEW; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY TERMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

EID: 37049002866     PISSN: 10153837     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109223     Document Type: Article

References (22)

1. Wald NJ, Watt HC, Hackshaw AK: Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;12:461-467.
2. Rozenberg P, Bussieres L, Chevret S, Bernard JP, Malagrida L, Cuckle H, Chabry C, Durand-Zaleski I, Bidat L, Lacroix I, Moulis M, Roger M, Jacquemot MC, Bault JP, Boukobza P, Boccara P, Vialard F, Giudicelli Y, Ville Y: Screening for Down syndrome using first trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 2006;195:1379-1387.
3. Schuchter K, Hafner E, Stangl G, Ogris E, Philipp K: Sequential screening for trisomy-21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Ultrasound Obstet Gynecol 2001;18:23-25.
4. Cuckle H: Integrating antenatal Down's syndrome screening. Curr Opin Obstet Gynecol 2001;13:175-181.
5. Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH: Prospective first-trimester screening for trisomy-21 in 30,564 pregnancies. Am J Obstet Gynecol 2005;192:1761-1767.
6. The Canadian Early and Mid-Trimester Amniocentesis Trial (CEMAT) Group: Randomized trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998;351:242-247.
7. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B: Randomised controlled trial of genetic amniocentesis in 4,606 low-risk women. Lancet 1986;1:1287-1293.
8. Fisk NM, Fordham K, Abramsky L: Elective late fetal karyotyping. Br J Obstet Gynaecol 1996;103:468-470.
9. Shalev J, Meizner I, Rabinerson D, Mashiah R, Peleg D, Orvieto R, Levi T et al: Elective cytogenetic amniocentesis in the third trimester for pregnancies with high risk factors. Prenat Diagn 1999;19:749-752.
10. Piiroinen O, Erkkola R, Gronroos M: Low-risk amniocentesis in the third trimester under ultrasound control. Eur J Radiol 1984;4:309-311.
11. Gordon MC, Narula K, O'Shaughnessy R, Bath W: Complications of third trimester amniocentesis using continuous ultrasound guidance. Obstet Gynecol 2002;99:255-259.
12. Stark CM, Smith RS, Lagrandeur RM, Batton DG, Lorenz RP: Need for urgent delivery after third trimester amniocentesis. Obstet Gynecol 2000;95:48-50.
13. Hodor JG, Poggi SH, Spong CY, Goodwin KM, Vink JS, Pezzullo JC, Ghidini A: Risk of third-trimester amniocentesis: a case-control study. Am J Perinatol 2006;23:177-180.
14. Mathews T, Verma RS: Enhancement of amniotic fluid cell growth for genetic amniocentesis. Clin Genet 1991;40:190-193.
15. Enquête périnatale française, 2003 http://www.sante.gouv.fr/htm/dossiers/perinat03/sommaire.htm
16. Kong CW, Leung TN, Leung TY, Chan LW, Sahota DS, Fung TY, Lau TK: Risk factors for procedure-related fetal losses after mid-trimester genetic amniocentesis. Prenat Diagn 2006;26:925-930.
17. Mungen E, Tutuncu L, Muhcu M, Yergok YZ: Pregnancy outcome following second-trimester amniocentesis: a case-control study. Am J Perinatol 2006;23:25-30.
18. Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R: Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Ultrasound Obstet Gynecol 2001;18:26-31.
19. Khoshnood B, De Vigan C, Vodovar V, Goujard J, Goffinet F: A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000. BJOG 2004;111:485-490.
20. Blondel B, Norton J, Du Mazaubrun C, Breart G: Evolution des principaux indicateurs de santé périnatale en France métropolitaine entre 1995 et 1998. J Gynecol Obstet Bio Reprod (Paris) 2001;30:552-564.
21. Leung WC, Waters JJ, Chitty L: Prenatal diagnosis by rapid aneuploidy detection and karyotyping: a prospective study of the role of ultrasound in 1,589 second-trimester amniocentesis. Prenat Diagn 2004;24:790-795.
22. Vintzileos AM, Guzman ER, Smulian JC, Yeo L, Scorza WE, Knuppel RA: Down syndrome risk estimation after normal genetic sonography. Am J Obstet Gynecol 2002;187:1226-1229.